Evidence map›Paper›PMID 30730943›Full record

ArticlePloS one2019

AHRR (cg05575921) methylation extent of leukocyte DNA and lung cancer survival.

Katja Kemp Jacobsen, Jakob Sidenius Johansen, Anders Mellemgaard, Stig Egil Bojesen

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Blood LeukocyteCancer research communications · 2023
    Article
  3. Article
  4. Article
  5. Ten Years of EWAS.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Katja Kemp JacobsenDepartment of Technology, Faculty of Health and Technology, University College Copenhagen, Copenhagen, Denmark.ORCID 0000-0002-0680-9631
Jakob Sidenius JohansenDepartment of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark.
Anders MellemgaardDepartment of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark.
Stig Egil BojesenDepartment of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, and Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Gentofte Hospital · DKUniversity College Copenhagen · DKUniversity of Copenhagen · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrior studies have shown that AHRR (cg05575921) hypomethylation may be a marker of smoking, lung cancer risk and potentially lung cancer survival (in some lung cancer subtypes). It is unknown if AHRR (cg05575921) hypomethylation is associated with reduced survival among lung cancer patients.

methodsIn bisulfite treated leukocyte DNA from 465 lung cancer patients from the Copenhagen prospective lung cancer study, we measured AHRR (cg05575921) methylation. 380 died during max follow-up of 4.4 years. Cox proportional hazard models were used to analyze survival as a function of AHRR (cg05575921) methylation.

resultsWe observed the expected inverse correlation between cumulative smoking and AHRR methylation, as methylation (%) decreased (Coefficient -0.03; 95% confidence interval, -0.04- -0.02, p = 8.6x10-15) for every pack-year. Cumulative smoking > 60 pack-years was associated with reduced survival (hazard ratio and 95% confidence interval 1.48; 1.05-2.09), however, AHRR (cg05575921) methylation was not associated with survival when adjusted for sex, body mass index, smoking status, ethnicity, performance status, TNM Classification, and histology type of lung cancer.

conclusionAHRR (cg05575921) methylation is linked to smoking but does not provide independent prognostic information in lung cancer patients.

Indexed as

DNA MethylationAgedBasic Helix-Loop-Helix ProteinsBiomarkers, TumorDisease-Free SurvivalDNA, NeoplasmFemaleHumansLeukocytesLung NeoplasmsMaleMiddle AgedNeoplasm ProteinsProspective StudiesRepressor ProteinsSmokingAHRR protein, humanBasic Helix-Loop-Helix ProteinsBiomarkers, TumorDNA, NeoplasmNeoplasm ProteinsRepressor Proteins

Identifiers

PMID30730943
PMCPMC6366765
OpenAlexW2913918832

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.